@saibolla/ada 0.1.2

package/skills/clinical-decision-support/references/outcome_analysis.md

@@ -0,0 +1,640 @@
+# Outcome Analysis and Statistical Methods Guide
+
+## Overview
+
+Rigorous outcome analysis is essential for clinical decision support documents. This guide covers survival analysis, response assessment, statistical testing, and data visualization for patient cohort analyses and treatment evaluation.
+
+## Survival Analysis
+
+### Kaplan-Meier Method
+
+**Overview**
+- Non-parametric estimator of survival function from time-to-event data
+- Handles censored observations (patients alive at last follow-up)
+- Provides survival probability at each time point
+- Generates characteristic step-function survival curves
+
+**Key Concepts**
+
+**Censoring**
+- **Right censoring**: Most common - patient alive at last follow-up or study end
+- **Left censoring**: Rare in clinical studies
+- **Interval censoring**: Event occurred between two assessment times
+- **Informative vs non-informative**: Censoring should be independent of outcome
+
+**Survival Function S(t)**
+- S(t) = Probability of surviving beyond time t
+- S(0) = 1.0 (100% alive at time zero)
+- S(t) decreases as time increases
+- Step decreases at each event time
+
+**Median Survival**
+- Time point where S(t) = 0.50
+- 50% of patients alive, 50% have had event
+- Reported with 95% confidence interval
+- "Not reached (NR)" if fewer than 50% events
+
+**Survival Rates at Fixed Time Points**
+- 1-year survival rate, 2-year survival rate, 5-year survival rate
+- Read from K-M curve at specific time point
+- Report with 95% CI: S(t) ± 1.96 × SE
+
+**Calculation Example**
+```
+Time  Events  At Risk  Survival Probability
+0     0       100      1.000
+3     2       100      0.980 (98/100)
+5     1       95       0.970 (97/100 × 95/98)
+8     3       87       0.936 (94/100 × 92/95 × 84/87)
+...
+```
+
+### Log-Rank Test
+
+**Purpose**: Compare survival curves between two or more groups
+
+**Null Hypothesis**: No difference in survival distributions between groups
+
+**Test Statistic**
+- Compares observed vs expected events in each group at each time point
+- Weights all time points equally
+- Follows chi-square distribution with df = k-1 (k groups)
+
+**Reporting**
+- Chi-square statistic, degrees of freedom, p-value
+- Example: χ² = 6.82, df = 1, p = 0.009
+- Interpretation: Significant difference in survival curves
+
+**Assumptions**
+- Censoring is non-informative and independent
+- Proportional hazards (constant HR over time)
+- If non-proportional, consider time-varying effects
+
+**Alternatives for Non-Proportional Hazards**
+- **Gehan-Breslow test**: Weights early events more heavily
+- **Peto-Peto test**: Modifies Gehan-Breslow weighting
+- **Restricted mean survival time (RMST)**: Difference in area under K-M curve
+
+### Cox Proportional Hazards Regression
+
+**Purpose**: Multivariable survival analysis, estimate hazard ratios adjusting for covariates
+
+**Model**: h(t|X) = h₀(t) × exp(β₁X₁ + β₂X₂ + ... + βₚXₚ)
+- h(t|X): Hazard rate for individual with covariates X
+- h₀(t): Baseline hazard function (unspecified)
+- exp(β): Hazard ratio for one-unit change in covariate
+
+**Hazard Ratio Interpretation**
+- HR = 1.0: No effect
+- HR > 1.0: Increased risk (harmful)
+- HR < 1.0: Decreased risk (beneficial)
+- HR = 0.50: 50% reduction in hazard (risk of event)
+
+**Example Output**
+```
+Variable              HR      95% CI         p-value
+Treatment (B vs A)    0.62    0.43-0.89      0.010
+Age (per 10 years)    1.15    1.02-1.30      0.021
+ECOG PS (2 vs 0-1)    1.85    1.21-2.83      0.004
+Biomarker+ (vs -)     0.71    0.48-1.05      0.089
+```
+
+**Proportional Hazards Assumption**
+- Hazard ratio constant over time
+- Test: Schoenfeld residuals, log-minus-log plots
+- Violation: Time-varying effects, consider stratification or time-dependent covariates
+
+**Multivariable vs Univariable**
+- **Univariable**: One covariate at a time, unadjusted HRs
+- **Multivariable**: Multiple covariates simultaneously, adjusted HRs
+- Report both: Univariable for all variables, multivariable for final model
+
+**Model Selection**
+- **Forward selection**: Start with empty model, add significant variables
+- **Backward elimination**: Start with all variables, remove non-significant
+- **Clinical judgment**: Include known prognostic factors regardless of p-value
+- **Parsimony**: Avoid overfitting, rule of thumb 1 variable per 10-15 events
+
+## Response Assessment
+
+### RECIST v1.1 (Response Evaluation Criteria in Solid Tumors)
+
+**Target Lesions**
+- Select up to 5 lesions total (maximum 2 per organ)
+- Measurable: ≥10 mm longest diameter (≥15 mm for lymph nodes short axis)
+- Sum of longest diameters (SLD) at baseline
+
+**Response Categories**
+
+**Complete Response (CR)**
+- Disappearance of all target and non-target lesions
+- Lymph nodes must regress to <10 mm short axis
+- Confirmation required at ≥4 weeks
+
+**Partial Response (PR)**
+- ≥30% decrease in SLD from baseline
+- No new lesions or unequivocal progression of non-target lesions
+- Confirmation required at ≥4 weeks
+
+**Stable Disease (SD)**
+- Neither PR nor PD criteria met
+- Minimum duration typically 6-8 weeks from baseline
+
+**Progressive Disease (PD)**
+- ≥20% increase in SLD AND ≥5 mm absolute increase from smallest SLD (nadir)
+- OR appearance of new lesions
+- OR unequivocal progression of non-target lesions
+
+**Example Calculation**
+```
+Baseline SLD: 80 mm (4 target lesions)
+Week 6 SLD: 52 mm
+
+Percent change: (52 - 80)/80 × 100% = -35%
+Classification: Partial Response (≥30% decrease)
+
+Week 12 SLD: 48 mm (nadir)
+Week 18 SLD: 62 mm
+
+Percent change from nadir: (62 - 48)/48 × 100% = +29%
+Absolute change: 62 - 48 = 14 mm
+Classification: Progressive Disease (>20% AND ≥5 mm increase)
+```
+
+### iRECIST (Immune RECIST)
+
+**Purpose**: Account for atypical response patterns with immunotherapy
+
+**Modifications from RECIST v1.1**
+
+**iUPD (Immune Unconfirmed Progressive Disease)**
+- Initial increase in tumor burden or new lesions
+- Requires confirmation at next assessment (≥4 weeks later)
+- Continue treatment if clinically stable
+
+**iCPD (Immune Confirmed Progressive Disease)**
+- Confirmed progression at repeat imaging
+- Discontinue immunotherapy
+
+**Pseudoprogression**
+- Initial apparent progression followed by response
+- Mechanism: Immune cell infiltration increases tumor size
+- Incidence: 5-10% of patients on immunotherapy
+- Management: Continue treatment if patient clinically stable
+
+**New Lesions**
+- Record size and location but continue treatment
+- Do not automatically classify as PD
+- Confirm progression if new lesions grow or additional new lesions appear
+
+### Other Response Criteria
+
+**Lugano Classification (Lymphoma)**
+- **PET-based**: Deauville 5-point scale
+  - Score 1-3: Negative (metabolic CR)
+  - Score 4-5: Positive (residual disease)
+- **CT-based**: If PET not available
+- **Bone marrow**: Required for staging in some lymphomas
+
+**RANO (Response Assessment in Neuro-Oncology)**
+- **Glioblastoma-specific**: Accounts for pseudoprogression with radiation/temozolomide
+- **Enhancing disease**: Bidimensional measurements (product of perpendicular diameters)
+- **Non-enhancing disease**: FLAIR changes assessed separately
+- **Corticosteroid dose**: Must document, increase may indicate progression
+
+**mRECIST (Modified RECIST for HCC)**
+- **Viable tumor**: Enhancing portion only (arterial phase enhancement)
+- **Necrosis**: Non-enhancing areas excluded from measurements
+- **Application**: Hepatocellular carcinoma with arterial enhancement
+
+## Outcome Metrics
+
+### Efficacy Endpoints
+
+**Overall Survival (OS)**
+- **Definition**: Time from randomization/treatment start to death from any cause
+- **Advantages**: Objective, not subject to assessment bias, regulatory gold standard
+- **Disadvantages**: Requires long follow-up, affected by subsequent therapies
+- **Censoring**: Last known alive date
+- **Analysis**: Kaplan-Meier, log-rank test, Cox regression
+
+**Progression-Free Survival (PFS)**
+- **Definition**: Time from randomization to progression (RECIST) or death
+- **Advantages**: Earlier readout than OS, direct treatment effect
+- **Disadvantages**: Requires regular imaging, subject to assessment timing
+- **Censoring**: Last tumor assessment without progression
+- **Sensitivity Analysis**: Assess impact of censoring assumptions
+
+**Objective Response Rate (ORR)**
+- **Definition**: Proportion of patients achieving CR or PR (best response)
+- **Denominator**: Evaluable patients (baseline measurable disease)
+- **Reporting**: Percentage with 95% CI (exact binomial method)
+- **Duration**: Time from first response to progression (DOR)
+- **Advantage**: Binary endpoint, no censoring complications
+
+**Disease Control Rate (DCR)**
+- **Definition**: CR + PR + SD (stable disease ≥6-8 weeks)
+- **Less Stringent**: Captures clinical benefit beyond objective response
+- **Reporting**: Percentage with 95% CI
+
+**Duration of Response (DOR)**
+- **Definition**: Time from first CR or PR to progression (among responders only)
+- **Population**: Subset analysis of responders
+- **Analysis**: Kaplan-Meier among responders
+- **Reporting**: Median DOR with 95% CI
+
+**Time to Treatment Failure (TTF)**
+- **Definition**: Time from start to discontinuation for any reason (progression, toxicity, death, patient choice)
+- **Advantage**: Reflects real-world treatment duration
+- **Components**: PFS + toxicity-related discontinuations
+
+### Safety Endpoints
+
+**Adverse Events (CTCAE v5.0)**
+
+**Grading**
+- **Grade 1**: Mild, asymptomatic or mild symptoms, clinical intervention not indicated
+- **Grade 2**: Moderate, minimal/local intervention indicated, age-appropriate ADL limitation
+- **Grade 3**: Severe or medically significant, not immediately life-threatening, hospitalization/prolongation indicated, disabling, self-care ADL limitation
+- **Grade 4**: Life-threatening consequences, urgent intervention indicated
+- **Grade 5**: Death related to adverse event
+
+**Reporting Standards**
+```
+Adverse Event Summary Table:
+
+AE Term (MedDRA)        Any Grade, n (%)  Grade 3-4, n (%)  Grade 5, n (%)
+                        Trt A    Trt B    Trt A   Trt B     Trt A   Trt B
+─────────────────────────────────────────────────────────────────────────
+Hematologic
+  Anemia                45 (90%) 42 (84%) 8 (16%) 6 (12%)   0       0
+  Neutropenia           35 (70%) 38 (76%) 15 (30%) 18 (36%) 0       0
+  Thrombocytopenia      28 (56%) 25 (50%) 6 (12%) 4 (8%)    0       0
+  Febrile neutropenia   4 (8%)   6 (12%)  4 (8%)  6 (12%)   0       0
+
+Gastrointestinal
+  Nausea                42 (84%) 40 (80%) 2 (4%)  1 (2%)    0       0
+  Diarrhea              31 (62%) 28 (56%) 5 (10%) 3 (6%)    0       0
+  Mucositis             18 (36%) 15 (30%) 3 (6%)  2 (4%)    0       0
+
+Any AE                  50 (100%) 50 (100%) 38 (76%) 35 (70%) 1 (2%) 0
+```
+
+**Serious Adverse Events (SAEs)**
+- SAE incidence and type
+- Relationship to treatment (related vs unrelated)
+- Outcome (resolved, ongoing, fatal)
+- Causality assessment (definite, probable, possible, unlikely, unrelated)
+
+**Treatment Modifications**
+- Dose reductions: n (%), reason
+- Dose delays: n (%), duration
+- Discontinuations: n (%), reason (toxicity vs progression vs other)
+- Relative dose intensity: (actual dose delivered / planned dose) × 100%
+
+## Statistical Analysis Methods
+
+### Comparing Continuous Outcomes
+
+**Independent Samples t-test**
+- **Application**: Compare means between two independent groups (normally distributed)
+- **Assumptions**: Normal distribution, equal variances (or use Welch's t-test)
+- **Reporting**: Mean ± SD for each group, mean difference (95% CI), t-statistic, df, p-value
+- **Example**: Mean age 62.3 ± 8.4 vs 58.7 ± 9.1 years, difference 3.6 years (95% CI 0.2-7.0, p=0.038)
+
+**Mann-Whitney U Test (Wilcoxon Rank-Sum)**
+- **Application**: Compare medians between two groups (non-normal distribution)
+- **Non-parametric**: No distributional assumptions
+- **Reporting**: Median [IQR] for each group, median difference, U-statistic, p-value
+- **Example**: Median time to response 6.2 [4.1-8.3] vs 8.5 [5.9-11.2] weeks, p=0.042
+
+**ANOVA (Analysis of Variance)**
+- **Application**: Compare means across three or more groups
+- **Output**: F-statistic, p-value (overall test)
+- **Post-hoc**: If significant, pairwise comparisons with Tukey or Bonferroni correction
+- **Example**: Treatment effect varied by biomarker subgroup (F=4.32, df=2, p=0.016)
+
+### Comparing Categorical Outcomes
+
+**Chi-Square Test for Independence**
+- **Application**: Compare proportions between two or more groups
+- **Assumptions**: Expected count ≥5 in at least 80% of cells
+- **Reporting**: n (%) for each cell, χ², df, p-value
+- **Example**: ORR 45% vs 30%, χ²=6.21, df=1, p=0.013
+
+**Fisher's Exact Test**
+- **Application**: 2×2 tables when expected count <5
+- **Exact p-value**: No large-sample approximation
+- **Two-sided vs one-sided**: Typically report two-sided
+- **Example**: SAE rate 3/20 (15%) vs 8/22 (36%), Fisher's exact p=0.083
+
+**McNemar's Test**
+- **Application**: Paired categorical data (before/after, matched pairs)
+- **Example**: Response before vs after treatment switch in same patients
+
+### Sample Size and Power
+
+**Power Analysis Components**
+- **Alpha (α)**: Type I error rate, typically 0.05 (two-sided)
+- **Beta (β)**: Type II error rate, typically 0.10 or 0.20
+- **Power**: 1 - β, typically 0.80 or 0.90 (80-90% power)
+- **Effect size**: Expected difference (HR, mean difference, proportion difference)
+- **Sample size**: Number of patients or events needed
+
+**Survival Study Sample Size**
+- Events-driven: Need sufficient events (deaths, progressions)
+- Rule of thumb: 80% power requires approximately 165 events for HR=0.70 (α=0.05, two-sided)
+- Accrual time + follow-up time determines calendar time
+
+**Response Rate Study**
+```
+Example: Detect ORR difference 45% vs 30% (15 percentage points)
+- α = 0.05 (two-sided)
+- Power = 0.80
+- Sample size: n = 94 per group (188 total)
+- With 10% dropout: n = 105 per group (210 total)
+```
+
+## Data Visualization
+
+### Survival Curves
+
+**Kaplan-Meier Plot Best Practices**
+
+```python
+# Key elements for publication-quality survival curve
+1. X-axis: Time (months or years), starts at 0
+2. Y-axis: Survival probability (0 to 1.0 or 0% to 100%)
+3. Step function: Survival curve with steps at event times
+4. 95% CI bands: Shaded region around survival curve (optional but recommended)
+5. Number at risk table: Below x-axis showing n at risk at time intervals
+6. Censoring marks: Vertical tick marks (|) at censored observations
+7. Legend: Clearly identify each curve
+8. Log-rank p-value: Prominently displayed
+9. Median survival: Horizontal line at 0.50, labeled
+10. Follow-up: Median follow-up time reported
+```
+
+**Number at Risk Table Format**
+```
+Number at risk
+Group A   50    42    35    28    18    10     5
+Group B   48    38    29    19    12     6     2
+Time      0     6     12    18    24    30    36 (months)
+```
+
+**Hazard Ratio Annotation**
+```
+On plot: HR 0.62 (95% CI 0.43-0.89), p=0.010
+Or in caption: Log-rank test p=0.010; Cox model HR=0.62 (95% CI 0.43-0.89)
+```
+
+### Waterfall Plots
+
+**Purpose**: Visualize individual patient responses to treatment
+
+**Construction**
+- **X-axis**: Individual patients (anonymized patient IDs)
+- **Y-axis**: Best % change from baseline tumor burden
+- **Bars**: Vertical bars, one per patient
+  - Positive values: Tumor growth
+  - Negative values: Tumor shrinkage
+- **Ordering**: Sorted from best response (left) to worst (right)
+- **Color coding**:
+  - Green/blue: CR or PR (≥30% decrease)
+  - Yellow: SD (-30% to +20%)
+  - Red: PD (≥20% increase)
+- **Reference lines**: Horizontal lines at +20% (PD), -30% (PR)
+- **Annotations**: Biomarker status, response duration (symbols)
+
+**Example Annotations**
+```
+■ = Biomarker-positive
+○ = Biomarker-negative
+* = Ongoing response
+† = Progressed
+```
+
+### Forest Plots
+
+**Purpose**: Display subgroup analyses with hazard ratios and confidence intervals
+
+**Construction**
+- **Y-axis**: Subgroup categories
+- **X-axis**: Hazard ratio (log scale), vertical line at HR=1.0
+- **Points**: HR estimate for each subgroup
+- **Horizontal lines**: 95% confidence interval
+- **Square size**: Proportional to sample size or precision
+- **Overall effect**: Diamond at bottom, width represents 95% CI
+
+**Subgroups to Display**
+```
+Subgroup                    n     HR (95% CI)          Favors A  Favors B
+──────────────────────────────────────────────────────────────────────────
+Overall                     300   0.65 (0.48-0.88)         ●────┤
+Age
+  <65 years                 180   0.58 (0.39-0.86)        ●────┤
+  ≥65 years                 120   0.78 (0.49-1.24)          ●──────┤
+Sex
+  Male                      175   0.62 (0.43-0.90)        ●────┤
+  Female                    125   0.70 (0.44-1.12)         ●─────┤
+Biomarker Status
+  Positive                  140   0.45 (0.28-0.72)      ●───┤
+  Negative                  160   0.89 (0.59-1.34)           ●──────┤
+                                  p-interaction=0.041
+
+                                  0.25  0.5   1.0   2.0
+                                        Hazard Ratio
+```
+
+**Interaction Testing**
+- Test whether treatment effect differs across subgroups
+- p-interaction <0.05 suggests heterogeneity
+- Pre-specify subgroups to avoid data mining
+
+### Spider Plots
+
+**Purpose**: Display longitudinal tumor burden changes over time for individual patients
+
+**Construction**
+- **X-axis**: Time from treatment start (weeks or months)
+- **Y-axis**: % change from baseline tumor burden
+- **Lines**: One line per patient connecting assessments
+- **Color coding**: By response category or biomarker status
+- **Reference lines**: 0% (no change), +20% (PD threshold), -30% (PR threshold)
+
+**Clinical Insights**
+- Identify delayed responders (initial SD then PR)
+- Detect early progression (rapid upward trajectory)
+- Assess depth of response (maximum tumor shrinkage)
+- Duration visualization (when lines cross PD threshold)
+
+### Swimmer Plots
+
+**Purpose**: Display treatment duration and response for individual patients
+
+**Construction**
+- **X-axis**: Time from treatment start (weeks or months)
+- **Y-axis**: Individual patients (one row per patient)
+- **Bars**: Horizontal bars representing treatment duration
+- **Symbols**:
+  - ● Start of treatment
+  - ▼ Ongoing treatment (arrow)
+  - ■ Progressive disease (end of bar)
+  - ◆ Death
+  - | Dose modification
+- **Color**: Response status (CR=green, PR=blue, SD=yellow, PD=red)
+
+**Example**
+```
+Patient ID    |0   3   6   9   12  15  18  21  24 months
+──────────────|──────────────────────────────────────────
+Pt-001        ●═══PR═══════════|════════PR══════════▼
+Pt-002        ●═══PR═══════════════PD■
+Pt-003        ●══════SD══════════PD■
+Pt-004        ●PR══════════════════════════════════PR▼
+...
+```
+
+## Confidence Intervals
+
+### Interpretation
+
+**95% Confidence Interval**
+- Range of plausible values for true population parameter
+- If study repeated 100 times, 95 of the 95% CIs would contain true value
+- **Not**: 95% probability true value within this interval (frequentist, not Bayesian)
+
+**Relationship to p-value**
+- If 95% CI excludes null value (HR=1.0, difference=0), p<0.05
+- If 95% CI includes null value, p≥0.05
+- CI provides more information: magnitude and precision of effect
+
+**Precision**
+- **Narrow CI**: High precision, large sample size
+- **Wide CI**: Low precision, small sample size or high variability
+- **Example**: HR 0.65 (95% CI 0.62-0.68) very precise; HR 0.65 (0.30-1.40) imprecise
+
+### Calculation Methods
+
+**Hazard Ratio CI**
+- From Cox regression output
+- Standard error of log(HR) → exp(log(HR) ± 1.96×SE)
+- Example: HR=0.62, SE(logHR)=0.185 → 95% CI (0.43, 0.89)
+
+**Survival Rate CI (Greenwood Formula)**
+- SE(S(t)) = S(t) × sqrt(Σ[d_i / (n_i × (n_i - d_i))])
+- 95% CI: S(t) ± 1.96 × SE(S(t))
+- Can use complementary log-log transformation for better properties
+
+**Proportion CI (Exact Binomial)**
+- For ORR, DCR: Use exact method (Clopper-Pearson) for small samples
+- Wilson score interval: Better properties than normal approximation
+- Example: 12/30 responses → ORR 40% (95% CI 22.7-59.4%)
+
+## Censoring and Missing Data
+
+### Types of Censoring
+
+**Right Censoring**
+- **End of study**: Patient alive at study termination (administrative censoring)
+- **Loss to follow-up**: Patient stops attending visits
+- **Withdrawal**: Patient withdraws consent
+- **Competing risk**: Death from unrelated cause (in disease-specific survival)
+
+**Handling Censoring**
+- **Assumption**: Non-informative - censoring independent of event probability
+- **Sensitivity Analysis**: Assess impact if assumption violated
+  - Best case: All censored patients never progress
+  - Worst case: All censored patients progress immediately after censoring
+  - Actual result should fall between best/worst case
+
+### Missing Data
+
+**Mechanisms**
+- **MCAR (Missing Completely at Random)**: Missingness unrelated to any variable
+- **MAR (Missing at Random)**: Missingness related to observed but not unobserved variables
+- **NMAR (Not Missing at Random)**: Missingness related to the missing value itself
+
+**Handling Strategies**
+- **Complete case analysis**: Exclude patients with missing data (biased if not MCAR)
+- **Multiple imputation**: Generate multiple plausible datasets, analyze each, pool results
+- **Maximum likelihood**: Estimate parameters using all available data
+- **Sensitivity analysis**: Assess robustness to missing data assumptions
+
+**Response Assessment Missing Data**
+- **Unevaluable for response**: Baseline measurable disease but post-baseline assessment missing
+  - Exclude from ORR denominator or count as non-responder (sensitivity analysis)
+- **PFS censoring**: Last adequate tumor assessment date if later assessments missing
+
+## Reporting Standards
+
+### CONSORT Statement (RCTs)
+
+**Flow Diagram**
+- Assessed for eligibility (n=)
+- Randomized (n=)
+- Allocated to intervention (n=)
+- Lost to follow-up (n=, reasons)
+- Discontinued intervention (n=, reasons)
+- Analyzed (n=)
+
+**Baseline Table**
+- Demographics and clinical characteristics
+- Baseline prognostic factors
+- Show balance between arms
+
+**Outcomes Table**
+- Primary endpoint results with CI and p-value
+- Secondary endpoints
+- Safety summary
+
+### STROBE Statement (Observational Studies)
+
+**Study Design**: Cohort, case-control, or cross-sectional
+
+**Participants**: Eligibility, sources, selection methods, sample size
+
+**Variables**: Clearly define outcomes, exposures, predictors, confounders
+
+**Statistical Methods**: Describe all methods, handling of missing data, sensitivity analyses
+
+**Results**: Participant flow, descriptive data, outcome data, main results, other analyses
+
+### Reproducible Research Practices
+
+**Statistical Analysis Plan (SAP)**
+- Pre-specify all analyses before data lock
+- Primary and secondary endpoints
+- Analysis populations (ITT, per-protocol, safety)
+- Statistical tests and models
+- Subgroup analyses (pre-specified)
+- Interim analyses (if planned)
+- Multiple testing procedures
+
+**Transparency**
+- Report all pre-specified analyses
+- Distinguish pre-specified from post-hoc exploratory
+- Report both positive and negative results
+- Provide access to anonymized individual patient data (when possible)
+
+## Software and Tools
+
+### R Packages for Survival Analysis
+- **survival**: Core package (Surv, survfit, coxph, survdiff)
+- **survminer**: Publication-ready Kaplan-Meier plots (ggsurvplot)
+- **rms**: Regression modeling strategies
+- **flexsurv**: Flexible parametric survival models
+
+### Python Libraries
+- **lifelines**: Kaplan-Meier, Cox regression, survival curves
+- **scikit-survival**: Machine learning for survival analysis
+- **matplotlib**: Custom survival curve plotting
+
+### Statistical Software
+- **R**: Most comprehensive for survival analysis
+- **Stata**: Medical statistics, good for epidemiology
+- **SAS**: Industry standard for clinical trials
+- **GraphPad Prism**: User-friendly for basic analyses
+- **SPSS**: Point-and-click interface, limited survival features
+